---
title: "Rafael Holdings, Inc. 3Q 2026: Revenue $179K, EPS ($0.08) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289464865.md"
description: "Rafael Holdings reported Q3 2026 revenue of $179K, down 50.6% YoY, with a net loss of $4.23M and diluted EPS of ($0.08). The company advanced its lead candidate Trappsol Cyclo into Phase 3 trials for NPC1 and received FDA clearance for the VECTR System. R&D spending increased to support clinical development, while management evaluates non-core assets to focus on strategic therapeutic investments."
datetime: "2026-06-11T12:21:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289464865.md)
  - [en](https://longbridge.com/en/news/289464865.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289464865.md)
---

# Rafael Holdings, Inc. 3Q 2026: Revenue $179K, EPS ($0.08) — 10-Q Summary

Rafael Holdings, Inc. reported third-quarter 2026 results showing revenue of $179K and a net loss of ($4.23M), or diluted EPS of ($0.08), compared with revenue of $362K and a net loss of ($4.78M), or EPS of ($0.19), in the prior-year quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$179K

$362K

(50.6%)

Net income²

($4.23M)

($4.78M)

11.6%

Diluted EPS³

($0.08)

($0.19)

57.9%

_¹ Reported as “Total revenue”. ² Reported as “Net loss attributable to Rafael Holdings, Inc.”. ³ Reported as “Loss per share attributable to common stockholders”._

**Business Highlights**

-   Lead product advancement: Completed the Cyclo merger and consolidated Trappsol® Cyclo™ as the company's lead candidate, advancing a pivotal Phase 3 trial for Niemann‑Pick disease type C1 (NPC1).
-   Revenue mix shift: Healthcare product revenue rose year over year for the nine-month period driven by Cyclo specialty chemicals, while Infusion Technology revenues declined following an asset sale.
-   R&D acceleration: Increased R&D spending to support Cyclo Phase 3 and ongoing clinical development activities.
-   Portfolio focus: Management is evaluating non-core holdings to concentrate resources on Trappsol® Cyclo™ and strategic therapeutic investments.
-   Regulatory milestone: Rafael Medical Devices received FDA 510(k) substantial equivalence clearance for the VECTR System for minimally invasive ligament/fascia release.

Original SEC Filing: Rafael Holdings, Inc. \[ RFL \] - 10-Q - Jun. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [RFL.US](https://longbridge.com/en/quote/RFL.US.md)

## Related News & Research

- [A2GOLD COMPLETES STRATEGIC CLAIM CONSOLIDATION AT TAYLOR SILVER-GOLD PROJECT | AUXXF Stock News](https://longbridge.com/en/news/289051762.md)
- [Flyte (VTAK) Makes Strategic Investment in Volato (SOAR)](https://longbridge.com/en/news/289073370.md)
- [ZAWYA: Hamad Bin Khalifa University and Imperial College London launch strategic environmental health partnership](https://longbridge.com/en/news/289187375.md)
- [TSMC Revenue Surges 30% in May on Relentless AI Demand. TSM Stock Is Still Undervalued Here.](https://longbridge.com/en/news/289669212.md)
- [12:37 ETSimpliSafe Strengthens Executive Leadership Team with Three Strategic Appointments](https://longbridge.com/en/news/289494022.md)